ProfileGDS5678 / 1437383_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 58% 45% 48% 45% 46% 50% 49% 45% 46% 46% 53% 46% 47% 47% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5511358
GSM967853U87-EV human glioblastoma xenograft - Control 23.0581145
GSM967854U87-EV human glioblastoma xenograft - Control 33.1363248
GSM967855U87-EV human glioblastoma xenograft - Control 42.9949845
GSM967856U87-EV human glioblastoma xenograft - Control 53.0308246
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2869850
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2599749
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.049445
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0443846
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0626946
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2851853
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0302146
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1163347
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1088347